Prestiq

# Prestiq ## Overview - **Classification**: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) - **Mechanism**: Potentiates neurotransmitter activity in the CNS by inhibiting the reuptake of both serotonin and norepinephrine. ## Primary Indications 1. **Major Depressive Disorder (MDD)** - Treatment of depressive episodes in adults. ## Adult Dosing ### Standard Dosing **Major Depressive Disorder (MDD)** - **Dose**: Start with **50 mg** - **Frequency**: Once daily - **Route**: Oral extended-release tablet - **Maximum Dose**: **100 mg/day** (no additional benefit beyond **50 mg/day** for most patients, but higher doses are approved) - **Special Considerations**: Swallow whole; do not crush, chew, or divide. ### Dose Adjustments - **Renal Impairment**: - CrCl **30-50 mL/min**: **50 mg every other day**. - CrCl **<30 mL/min**: **50 mg every other day**. Consider lower frequency/dose. - ESRD on hemodialysis: **50 mg every other day** on non-dialysis days. - **Hepatic Impairment**: - Moderate to Severe: **50 mg once daily**. Max dose for these patients is **100 mg/day**. - **Elderly Patients**: No specific dose adjustment needed, but monitor for adverse effects due to potential decreased clearance and increased sensitivity. ## Pediatric Dosing **Prestiq is NOT FDA-approved for use in pediatric patients for any indication.** - **Black Box Warning**: Antidepressants increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults (18-24 years) with MDD and other psychiatric disorders. - **Clinical Recommendation**: Use in pediatric populations is generally avoided unless potential benefits significantly outweigh risks, and under strict monitoring by a specialist. ### Neonates (0-28 days) - **Dose**: Not FDA approved for this age group. - **Special Notes**: Contraindicated. ### Infants (1-12 months) - **Dose**: Not FDA approved for this age group. - **Special Notes**: Contraindicated. ### Children (1-12 years) - **Dose**: Not FDA approved for this age group. - **Special Notes**: Increased risk of suicidal ideation and behavior. ### Adolescents (13-18 years) - **Dose**: Not FDA approved for this age group. - **Special Notes**: Increased risk of suicidal ideation and behavior. Careful risk/benefit assessment by a specialist if considering off-label use. ## Safety Information ### Contraindications - **Absolute**: Concurrent use or within **14 days** of discontinuing a Monoamine Oxidase Inhibitor (MAOI). - **Absolute**: Hypersensitivity to desvenlafaxine or venlafaxine. - **Absolute**: Uncontrolled narrow-angle glaucoma. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, dry mouth, sweating, dizziness, insomnia, constipation. - **Common (1-10%)**: Hypertension, sexual dysfunction, anxiety, tremors, somnolence. - **Serious but Rare**: Serotonin syndrome, suicidal thoughts/behavior, sustained hypertension, seizures, angle-closure glaucoma, hyponatremia, bleeding events. ### Key Drug Interactions - **MAOIs**: Increased risk of **serotonin syndrome** (hyperthermia, rigidity, myoclonus, autonomic instability). Avoid concurrent use. - **Other Serotonergic Drugs (SSRIs, SNRIs, triptans, tramadol, St. John's Wort)**: Increased risk of **serotonin syndrome**. Monitor closely. - **Anticoagulants/Antiplatelets (warfarin, NSAIDs)**: Increased risk of **bleeding**. Monitor for signs of bleeding. - **Ethanol**: May worsen CNS effects. Advise caution. ## Monitoring & Follow-up - **Before Treatment**: Assess for personal/family history of bipolar disorder, suicide risk, glaucoma, blood pressure. - **During Treatment**: - **Blood Pressure**: Monitor regularly, especially at initiation and dose increases. - **Mood/Behavior**: Monitor for worsening depression, suicidal ideation, agitation, mania/hypomania, especially in the first few weeks or with dose changes. - **Adverse Effects**: Assess for common and serious side effects. - **Sodium**: Periodically monitor serum sodium in patients at risk for hyponatremia. - **Clinical Signs**: Watch for signs of serotonin syndrome (agitation, confusion, tachycardia, fever, muscle rigidity, tremors). ## Clinical Pearls - 💡 **Administration**: Take **once daily** with or without food. Swallow whole, do not crush, chew, or divide. - 💡 **Withdrawal**: Do not abruptly discontinue; taper dose gradually to avoid SNRI discontinuation syndrome symptoms (dizziness, nausea, headache, paresthesia). - 💡 **Hypertension**: Monitor BP closely. Can cause sustained increases in BP. Pre-existing hypertension should be controlled before initiation. - 💡 **Ghost Tablet**: Patients may observe a "ghost tablet" or shell in stool, which is normal and indicates proper drug release. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.